
|Articles|July 1, 2004
ROSACEA DRUG TRIALS
CollaGenex Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration has approved two phase 3 clinical trials of Col-101, a once-daily, modified-released formulation of doxycycline, 40 mg, for treatment of rosacea.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Delgocitinib Advances to Phase 3 Evaluation for Lichen Sclerosus
2
The “6-7” Advances for Dermatologists to Look Forward to in 2026
3
Obagi Launches ALOHA Program to Capture Real-World Insights in Aesthetic Injectables
4
Atopia Therapeutics Reports Positive Preclinical Data for ATP-R13 as Disease-Modifying Oral AD Therapy
5



















